company background image
6883

Chengdu Olymvax Biopharmaceuticals SHSE:688319 Stock Report

Last Price

CN¥13.91

Market Cap

CN¥5.6b

7D

-1.0%

1Y

-57.4%

Updated

05 Oct, 2022

Data

Company Financials +
688319 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance3/6
Financial Health4/6
Dividends0/6

688319 Stock Overview

Olymvax Biopharmaceuticals Inc. develops and supplies vaccines.

Chengdu Olymvax Biopharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Chengdu Olymvax Biopharmaceuticals
Historical stock prices
Current Share PriceCN¥13.91
52 Week HighCN¥40.59
52 Week LowCN¥13.32
Beta0
1 Month Change-14.72%
3 Month Change-23.99%
1 Year Change-57.44%
3 Year Changen/a
5 Year Changen/a
Change since IPO-65.14%

Recent News & Updates

Shareholder Returns

688319CN BiotechsCN Market
7D-1.0%-1.0%-3.3%
1Y-57.4%-33.6%-19.2%

Return vs Industry: 688319 underperformed the CN Biotechs industry which returned -33.6% over the past year.

Return vs Market: 688319 underperformed the CN Market which returned -19.2% over the past year.

Price Volatility

Is 688319's price volatile compared to industry and market?
688319 volatility
688319 Average Weekly Movement4.7%
Biotechs Industry Average Movement5.0%
Market Average Movement5.8%
10% most volatile stocks in CN Market9.2%
10% least volatile stocks in CN Market3.8%

Stable Share Price: 688319 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 688319's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009443Shaowen Fanhttps://www.olymvax.com

Olymvax Biopharmaceuticals Inc. develops and supplies vaccines. The company offers vaccines for Tetanus, a deadly infectious disease that causes nervous system toxicity by toxigenic clostridium tetanus; and haemophilus influenzae type b. it also develops vaccines for Staphylococcus aureus, a pathogenic bacterium that causes hospital infection and community infection; and Group A streptococcus disease. The company was founded in 2009 and is based in Chengdu, China.

Chengdu Olymvax Biopharmaceuticals Fundamentals Summary

How do Chengdu Olymvax Biopharmaceuticals's earnings and revenue compare to its market cap?
688319 fundamental statistics
Market CapCN¥5.64b
Earnings (TTM)CN¥96.65m
Revenue (TTM)CN¥550.74m

58.3x

P/E Ratio

10.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
688319 income statement (TTM)
RevenueCN¥550.74m
Cost of RevenueCN¥37.92m
Gross ProfitCN¥512.82m
Other ExpensesCN¥416.17m
EarningsCN¥96.65m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.24
Gross Margin93.12%
Net Profit Margin17.55%
Debt/Equity Ratio11.4%

How did 688319 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 688319 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688319?

Other financial metrics that can be useful for relative valuation.

688319 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue9.7x
Enterprise Value/EBITDA50.2x
PEG Ratio1.4x

Price to Earnings Ratio vs Peers

How does 688319's PE Ratio compare to its peers?

688319 PE Ratio vs Peers
The above table shows the PE ratio for 688319 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average13.6x
603387 Getein Biotech
10.5xn/aCN¥5.9b
002880 Shenzhen Weiguang Biological Products
29.5xn/aCN¥6.0b
300485 Beijing Science Sun Pharmaceutical
9.5xn/aCN¥5.3b
688767 Hangzhou Biotest BiotechLtd
5xn/aCN¥5.0b
688319 Chengdu Olymvax Biopharmaceuticals
58.3x41.3%CN¥5.6b

Price-To-Earnings vs Peers: 688319 is expensive based on its Price-To-Earnings Ratio (58.3x) compared to the peer average (13.6x).


Price to Earnings Ratio vs Industry

How does 688319's PE Ratio compare vs other companies in the CN Biotechs Industry?

Price-To-Earnings vs Industry: 688319 is expensive based on its Price-To-Earnings Ratio (58.3x) compared to the CN Biotechs industry average (30x)


Price to Earnings Ratio vs Fair Ratio

What is 688319's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688319 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio58.3x
Fair PE Ratio36.3x

Price-To-Earnings vs Fair Ratio: 688319 is expensive based on its Price-To-Earnings Ratio (58.3x) compared to the estimated Fair Price-To-Earnings Ratio (36.3x).


Share Price vs Fair Value

What is the Fair Price of 688319 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 688319's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 688319's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Chengdu Olymvax Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


41.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688319's forecast earnings growth (41.3% per year) is above the savings rate (3.2%).

Earnings vs Market: 688319's earnings (41.3% per year) are forecast to grow faster than the CN market (25.8% per year).

High Growth Earnings: 688319's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688319's revenue (29.3% per year) is forecast to grow faster than the CN market (18.1% per year).

High Growth Revenue: 688319's revenue (29.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 688319's Return on Equity is forecast to be low in 3 years time (18.1%).


Discover growth companies

Past Performance

How has Chengdu Olymvax Biopharmaceuticals performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


52.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 688319 has a high level of non-cash earnings.

Growing Profit Margin: 688319's current net profit margins (17.5%) are higher than last year (17.3%).


Past Earnings Growth Analysis

Earnings Trend: 688319 has become profitable over the past 5 years, growing earnings by 52% per year.

Accelerating Growth: 688319's earnings growth over the past year (47.7%) is below its 5-year average (52% per year).

Earnings vs Industry: 688319 earnings growth over the past year (47.7%) exceeded the Biotechs industry 9.7%.


Return on Equity

High ROE: 688319's Return on Equity (11%) is considered low.


Discover strong past performing companies

Financial Health

How is Chengdu Olymvax Biopharmaceuticals's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 688319's short term assets (CN¥892.8M) exceed its short term liabilities (CN¥386.7M).

Long Term Liabilities: 688319's short term assets (CN¥892.8M) exceed its long term liabilities (CN¥38.9M).


Debt to Equity History and Analysis

Debt Level: 688319 has more cash than its total debt.

Reducing Debt: 688319's debt to equity ratio has increased from 2.2% to 11.4% over the past 5 years.

Debt Coverage: 688319's debt is not well covered by operating cash flow (12.6%).

Interest Coverage: 688319 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Chengdu Olymvax Biopharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Chengdu Olymvax Biopharmaceuticals Dividend Yield vs Market
How does Chengdu Olymvax Biopharmaceuticals dividend yield compare to the market?
SegmentDividend Yield
Company (Chengdu Olymvax Biopharmaceuticals)n/a
Market Bottom 25% (CN)0.5%
Market Top 25% (CN)2.2%
Industry Average (Biotechs)0.9%
Analyst forecast in 3 Years (Chengdu Olymvax Biopharmaceuticals)n/a

Notable Dividend: Unable to evaluate 688319's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 688319's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 688319's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 688319's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 688319 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

12.8yrs

Average management tenure


CEO

Shaowen Fan (69 yo)

12.75yrs

Tenure

Mr. Shaowen Fan is Genenral Manager & Chairman of the Board of Chengdu Olymvax Biopharmaceuticals Inc. since 2019.


Leadership Team

Experienced Management: 688319's management team is seasoned and experienced (12.8 years average tenure).


Board Members

Experienced Board: 688319's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 688319?
Owner TypeNumber of SharesOwnership Percentage
Institutions25,267,7046.2%
Private Companies84,294,33020.8%
Individual Insiders120,064,40329.6%
General Public175,638,56343.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 54.57% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
17.86%
Chongqing Wushan Biotechnology Co., Ltd.
72,394,330CN¥1.0b0%no data
7.28%
Fan Fan
29,489,220CN¥410.2m0%no data
6.39%
Pengfei Zhang
25,893,040CN¥360.2m0%no data
5%
Yu Zhang
20,263,160CN¥281.9m-12.46%no data
3.93%
Baolin Wang
15,922,077CN¥221.5m0%no data
3.85%
Shaowen Fan
15,592,795CN¥216.9m0%no data
2.94%
Shanghai Lianhuansheng Industry Co., Ltd.
11,900,000CN¥165.5m0%no data
2.74%
GF Xinde Investment Management Co., Ltd
11,106,610CN¥154.5m0%9.96%
1.64%
Cheng Hu
6,666,125CN¥92.7m0%no data
1.2%
Hengjun Ma
4,858,946CN¥67.6m0%no data
0.5%
Shanghai Panyao Asset Management Co., Ltd.
2,042,163CN¥28.4m0%1.97%
0.25%
CITIC Securities Company Limited, Asset Management Arm
1,003,534CN¥14.0m0%0.04%
0.17%
Shanghai Haitong Securities Asset Management Co., Ltd
672,789CN¥9.4m0%0.17%
0.16%
Shanghai L&R Asset Management Company Limited
634,000CN¥8.8m0%no data
0.13%
Great Wall Fund Management Co. Ltd.
544,582CN¥7.6m0%0.03%
0.097%
China International Capital Corporation Hong Kong Asset Management Limited
392,854CN¥5.5m0%0.04%
0.068%
Hongguang Li
277,440CN¥3.9m0%no data
0.068%
Yong Tan
277,440CN¥3.9m0%no data
0.051%
Lu Lu
208,080CN¥2.9m0%no data
0.051%
Aimin Chen
208,080CN¥2.9m0%no data
0.05%
Daoyuan Chen
204,000CN¥2.8m0%no data
0.05%
Wei Wu
204,000CN¥2.8m0%no data
0.038%
Golden Trust SinoPac Fund Management Co., Ltd.
152,000CN¥2.1m0%0.02%
0.034%
CPIC Fund Management Co., Ltd.
136,436CN¥1.9m0%0.01%
0.025%
Changsheng Fund Management Co., Ltd.
100,472CN¥1.4m0%0.01%

Company Information

Chengdu Olymvax Biopharmaceuticals Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Chengdu Olymvax Biopharmaceuticals Inc.
  • Ticker: 688319
  • Exchange: SHSE
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CN¥5.637b
  • Shares outstanding: 405.27m
  • Website: https://www.olymvax.com

Number of Employees


Location

  • Chengdu Olymvax Biopharmaceuticals Inc.
  • No. 99 Tianxin Road
  • Hi-Tech Zone (West)
  • Chengdu
  • Sichuan Province
  • 611731
  • China


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
688319SHSE (Shanghai Stock Exchange)YesDomestic SharesCNCNYJun 2021

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/05 00:00
End of Day Share Price2022/09/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.